Pulse Biosciences (NASDAQ:PLSE) Shares Up 7%

Pulse Biosciences, Inc. (NASDAQ:PLSE) shares were up 7% on Monday . The company traded as high as $18.52 and last traded at $18.40. Approximately 12,696 shares traded hands during mid-day trading, a decline of 94% from the average daily volume of 213,070 shares. The stock had previously closed at $17.19.

Analyst Upgrades and Downgrades

Separately, StockNews.com upgraded shares of Pulse Biosciences to a “sell” rating in a report on Tuesday, August 6th.

Pulse Biosciences Trading Down 1.8 %

The firm has a market cap of $1.06 billion, a price-to-earnings ratio of -21.27 and a beta of 1.75. The stock’s 50 day moving average is $16.79 and its 200 day moving average is $12.09.

Institutional Trading of Pulse Biosciences

Several hedge funds have recently added to or reduced their stakes in PLSE. Vanguard Group Inc. increased its position in Pulse Biosciences by 28.8% during the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock worth $7,379,000 after buying an additional 189,227 shares during the period. Griffin Asset Management Inc. grew its stake in shares of Pulse Biosciences by 15.7% in the first quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after acquiring an additional 40,700 shares in the last quarter. Westside Investment Management Inc. grew its stake in shares of Pulse Biosciences by 97.8% in the second quarter. Westside Investment Management Inc. now owns 63,600 shares of the company’s stock valued at $712,000 after acquiring an additional 31,440 shares in the last quarter. PNC Financial Services Group Inc. bought a new position in Pulse Biosciences during the fourth quarter worth about $242,000. Finally, Cetera Advisors LLC acquired a new stake in Pulse Biosciences in the 1st quarter worth about $109,000. 76.95% of the stock is owned by institutional investors and hedge funds.

About Pulse Biosciences

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.